v3.25.2
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)
 12 Months Ended
Feb. 23, 2022
Dec. 31, 2024
Dec. 31, 2023
Jun. 30, 2025
Jun. 28, 2023
Cash equivalents   $ 0 $ 0    
Deferred underwriting fee payable         $ 10,812,500
Federal deposit Insurance corporation coverage limit   250,000      
Unrecognized tax benefits   $ 0 $ 0    
Purchase price, per unit   $ 11.43      
Anti-dilutive securities attributable to warrants   24,138,333 24,138,333    
Additional paid in capital   $ 8,802,978 $ 10,964,930    
Aspire Biopharma Inc [Member]          
Common stock par value   $ 0.00005 $ 0.00005    
Post split par value     $ 0.00005    
Additional paid in capital   $ 1,215,113 $ 957,500    
Shares issued     150,000    
Aspire Biopharma Inc [Member] | Trademarks [Member]          
Amortization of long lived assets   4,844,982      
Parent Company [Member]          
Cash equivalents   0   $ 0  
Federal deposit Insurance corporation coverage limit       250,000  
Unrecognized tax benefits   $ 0   $ 0  
Common stock par value   $ 0.0001   $ 0.0001  
Additional paid in capital   $ 1,234,385   $ 11,078,116  
Previously Reported [Member] | Aspire Biopharma Inc [Member]          
Common stock par value   $ 0.01      
Additional paid in capital     $ 758,000    
Revision of Prior Period, Adjustment [Member] | Aspire Biopharma Inc [Member]          
Common stock par value     $ 0.001    
Additional paid in capital     $ 957,500    
Effect of Restatement [Member] | Aspire Biopharma Inc [Member]          
Additional paid in capital     $ 199,500    
Warrant [Member]          
Purchase of aggregate shares 24,138,333        
Purchase price, per unit $ 11.50        
Common Class A Subject to Redemption [Member]          
Ordinary shares subject to possible redemption   577,644 1,803,729    
IPO [Member]          
Offering costs   $ 16,418,580      
Underwriting fees   5,000,000      
Deferred underwriting fee payable   10,812,500      
Other costs   $ 606,080      
Purchase price, per unit $ 10.25